CMS Price Negotiation Could Tackle High-Cost Drugs, Economists Suggest
Executive Summary
Medicare should consider negotiating prices for drugs that are priced high for Part D relative to other selected payers, Johns Hopkins University Professor of Health Policy and Management Gerald Anderson advocated at a Jan. 11 Senate Finance Committee hearing
You may also be interested in...
Rx Importation Legislation Debate Begins Anew, But Battle Lines Are Familiar
Sens. Byron Dorgan, D-S.D., and Olympia Snowe, R-Maine, are trying to build momentum for their proposal to allow prescription drug importation, vowing at a March 7 hearing that they will push to bring the measure quickly to the Senate floor
Rx Importation Legislation Debate Begins Anew, But Battle Lines Are Familiar
Sens. Byron Dorgan, D-S.D., and Olympia Snowe, R-Maine, are trying to build momentum for their proposal to allow prescription drug importation, vowing at a March 7 hearing that they will push to bring the measure quickly to the Senate floor
Part D Plans With Most Enrollees Getting Deeper Discounts In ’07 – Astra Exec
The Medicare Part D prescription drug plans that enrolled the largest number of beneficiaries in 2006 have generally been able to extract deeper discounts from manufacturers in the second year of the drug benefit, AstraZeneca U.S. CEO Tony Zook said in an interview with "The Pink Sheet."